Tranzyme stomach paralysis drug fails mid-stage study, shares plunge

Thu Nov 15, 2012 9:17pm IST

Related Topics

(Reuters) - Tranzyme Inc said a preliminary analysis showed that its experimental drug to treat a type of paralysis of the stomach did not meet the main goal of a mid-stage trial, sending the company's shares to a life low.

The shares, which started trading on the Nasdaq at $4.00 in April last year, fell to $1.00 on Thursday after the initial results of the testing on Tranzyme's most advanced drug in development.

The main goal of the study was to reduce four symptoms in patients suffering from gastroparesis -- a condition that slows down the movement of food through the digestive tract due to paralysis of stomach muscles.

The trial was studying two doses of the drug, TZP-102, administered once a day for 12 weeks on diabetes patients. The drug was well tolerated, the company said.

JMP Securities analyst Liisa Bayko said the results were not surprising, since the odds of the trial meeting its endpoint were fifty-fifty.

"It's the first proof of concept mechanism in this disease, the drug came out on the wrong side, unfortunately," she said.

Tranzyme is currently conducting a second mid-stage trial to test a 10 mg dose of TZP-102 administered three times a day. The company expects results from the DIGEST trial in the first half of 2013.

Bayko said there was no overwhelmingly convincing evidence yet that the result of this trial would be positive.

TZP-102 is also in early-stage trials for the treatment of other chronic gastrointestinal motility disorders.

This setback comes after the company's experimental drug to improve gastrointestinal recovery after surgery failed to meet the main goals of a second late-stage trial in May.

The company had said at the time that it would focus on its drug to treat diabetic gastroparesis.

Shares of the company, which have risen about 23 percent since late May, closed at $3.97 on Wednesday on the Nasdaq.

(Editing by Roshni Menon and Rodney Joyce)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

HEALTH SHOWCASE

Breast Cancer Fight

Breast Cancer Fight

Roche, Merck extend immunotherapy fight to breast cancer  Full Article 

Office Perks

Office Perks

Apple, Facebook will pay for female employees to freeze their eggs.  Full Article 

It's In The Genes

It's In The Genes

Genetic link to Danish happiness, says study.  Video 

Smoking Effects

Smoking Effects

Americans have 14 million smoking-related ailments: study.  Full Article 

Health Food

Health Food

Olive oil, nuts may help reverse heart risk factors.  Full Article 

Digital Doctors

Digital Doctors

China sees tech cure for healthcare woes.  Full Article 

Stem Cell Study

Stem Cell Study

Stem cells from human embryos prove safe, improve vision - study.  Full Article 

Shortages Impact

Shortages Impact

Shortages hinder Venezuela's battle against fever outbreaks  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage